Calreticulin Arms NK Cells Against Leukemia

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2020 Feb 1

PMID 32002282

Citations 11

Authors

Jitka Fucikova

Justin P Kline

Lorenzo Galluzzi

Radek Spisek

Affiliations

Soon will be listed here.

Abstract

Calreticulin (CALR) exposed on the surface of cancer cells succumbing to therapy delivers robust phagocytic signals that support the activation of adaptive anticancer immune responses. Recent data from our group demonstrate that spontaneous CARL exposure on leukemic blasts also supports innate anticancer immunity by natural killer (NK) cells via an indirect mechanism relying on myeloid CD11cCD14 cells.

Citing Articles

The Oncolytic herpes simplex virus type-1 (HSV-1) vaccine strain VC2 causes intratumor infiltration of functionally active T cells and inhibition of tumor metastasis and pro-tumor genes VEGF and PDL1 expression in the 4T1/Balb/c mouse model of stage....

Nabi R, Musarrat F, Menk P Lima J, Langohr I, Chouljenko V, Kousoulas K Front Mol Biosci. 2023; 10:1199068.

PMID: 37388243 PMC: 10303929. DOI: 10.3389/fmolb.2023.1199068.

Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy.

Murugan D, Murugesan V, Panchapakesan B, Rangasamy L Cancers (Basel). 2022; 14(21).

PMID: 36358857 PMC: 9653801. DOI: 10.3390/cancers14215438.

Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.

Kofla G, Radecke C, Frentsch M, Walther W, Stintzing S, Riess H Oncoimmunology. 2022; 11(1):2068109.

PMID: 35496500 PMC: 9045824. DOI: 10.1080/2162402X.2022.2068109.

Immune Cell-Derived Extracellular Vesicles - New Strategies in Cancer Immunotherapy.

Yang P, Peng Y, Feng Y, Xu Z, Feng P, Cao J Front Immunol. 2021; 12:771551.

PMID: 34956197 PMC: 8694098. DOI: 10.3389/fimmu.2021.771551.

Trial watch: intratumoral immunotherapy.

Humeau J, Naour J, Galluzzi L, Kroemer G, Pol J Oncoimmunology. 2021; 10(1):1984677.

PMID: 34676147 PMC: 8526014. DOI: 10.1080/2162402X.2021.1984677.

References

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

Chen X, Fosco D, Kline D, Kline J . Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia. Oncoimmunology. 2017; 6(4):e1278332. PMC: 5414882. DOI: 10.1080/2162402X.2016.1278332. View

Yatim N, Cullen S, Albert M . Dying cells actively regulate adaptive immune responses. Nat Rev Immunol. 2017; 17(4):262-275. DOI: 10.1038/nri.2017.9. View

Forster R, Davalos-Misslitz A, Rot A . CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008; 8(5):362-71. DOI: 10.1038/nri2297. View

Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G . Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2016; 17(2):97-111. DOI: 10.1038/nri.2016.107. View

Castillo E, Stonier S, Frasca L, Schluns K . Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation. J Immunol. 2009; 183(8):4948-56. PMC: 5769454. DOI: 10.4049/jimmunol.0900719. View

Chiossone L, Dumas P, Vienne M, Vivier E . Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018; 18(11):671-688. DOI: 10.1038/s41577-018-0061-z. View

Husak Z, Dworzak M . CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity. Cell Death Dis. 2012; 3:e425. PMC: 3542600. DOI: 10.1038/cddis.2012.164. View

Lopez-Soto A, Gonzalez S, Smyth M, Galluzzi L . Control of Metastasis by NK Cells. Cancer Cell. 2017; 32(2):135-154. DOI: 10.1016/j.ccell.2017.06.009. View

10.

Truxova I, Kasikova L, Salek C, Hensler M, Lysak D, Holicek P . Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Haematologica. 2019; 105(7):1868-1878. PMC: 7327638. DOI: 10.3324/haematol.2019.223933. View

11.

Galluzzi L, Chan T, Kroemer G, Wolchok J, Lopez-Soto A . The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018; 10(459). DOI: 10.1126/scitranslmed.aat7807. View

12.

Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I . Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood. 2016; 128(26):3113-3124. PMC: 5201098. DOI: 10.1182/blood-2016-08-731737. View

13.

Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S . Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 2011; 1:e104. PMC: 3032293. DOI: 10.1038/cddis.2010.82. View